With the nutraceutical segment market growing at a healthy rate, the expected size of the market in 2015 is $243B. Chromadex, which supplies phytochemical reference standards (small quantities of plant-based compounds for research) is on a growth path as far as the volumes are concerned. The launch of BluScience range of dietary supplement products has been successful and has given further fillip to its sales. The range contains pTeroPure (pterostilbene) which is CDXC's proprietary patented product. PteroPure has been found to be helpful in blood pressure. The technology has been licensed from University of Mississippi and the USDA and the product can also be used for memory improvement, anxiety, and neuro-protection. It has been hailed as a very promising ingredient with potential of around $500 million in sales. Other compounds in pipeline are C3G, an anthocyanin, or nicotinamide riboside (no-flush vitamin) which have commercial potential. Regarding its expansion plans, Chromadex plans to increase R&D and sales / marketing efforts. The rising sales have, however, not translated into profits which is the main reason for its financial woes. The company is now focusing on cutting costs to reduce working capital and capex requirements. Expected sales in Q4'12 are likely to be robust and the improved cost structure is likely to help the company reach closer the the break-even point on net basis. Thankfully, the company has very little debt on books ($ 225,000). The interest payments are, hence, very low compared to the sales. Thus, CDXC would do great if it could concentrate on reducing its General & Administrative expenses which comprise of majority of its expenses. Insiders are holding 44% of the company stock which indicates some amount of faith in the future prospects. This stock, which is currently trading around $0.80 and $0.69 should act as a support as it is the 200DMA. CDXC can be bought within this range.